UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC 13D and 13G filings for Prelude Therapeutics Incorporated:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-13 1:49 pm Purchase | 2023-12-31 | 13G | PRELUDE THERAPEUTICS INC PRLD | UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 12,265,852 5.421% | 12,265,852 (New Position) | Filing |
| 2024-02-13 1:34 pm Sale | 2023-12-31 | 13G | PRELUDE THERAPEUTICS INC PRLD | UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 0 0.000% | -2,507,992 (Position Closed) | Filing |
| 2023-02-13 10:52 am Sale | 2022-12-30 | 13G | PRELUDE THERAPEUTICS INC PRLD | UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 2,507,992 5.240% | -14,054,454 (-84.86%) | Filing |
| 2023-02-13 10:49 am Purchase | 2022-12-30 | 13G | PRELUDE THERAPEUTICS INC PRLD | UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 16,562,446 6.620% | 16,562,446 (New Position) | Filing |